Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS007
MIFTS: 58

Plasmodium Falciparum Malaria

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Plasmodium Falciparum Malaria

About this section

MalaCards integrated aliases for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 12 15 17
Malaria, Falciparum 45 74
Falciparum Malaria 12 15
Malaria Fever, Subtertian 12
Malignant Tertian Fever 12
Malaria Falciparum 56

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:14067
ICD9CM 36 084.0
MeSH 45 D016778
NCIt 51 C34798
SNOMED-CT 69 62676009
ICD10 34 B50 B50.0 B50.9
UMLS 74 C0024535
Sources

Summaries for Plasmodium Falciparum Malaria

About this section
Disease Ontology : 12 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary : Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to hepatitis a and human immunodeficiency virus infectious disease. An important gene associated with Plasmodium Falciparum Malaria is CR1 (Complement C3b/C4b Receptor 1 (Knops Blood Group)), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Amodiaquine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for Plasmodium Falciparum Malaria

About this section

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 hepatitis a 30.8 IFNG IL10 TNF
2 human immunodeficiency virus infectious disease 30.8 IFNG IL10 TNF
3 aspergillosis 30.8 IFNG IL10 TNF
4 schistosomiasis 30.8 IFNG IL10 TNF
5 q fever 30.6 IFNG IL10 TNF
6 pulmonary edema 30.6 ICAM1 IL10 TNF
7 brucellosis 30.4 IFNG IL10 IL18 TNF
8 meningitis 30.3 FCGR2A IFNG IL10 TNF
9 leptospirosis 30.3 IFNG IL10 TNF
10 acquired immunodeficiency syndrome 30.3 IFNG IL10 TNF
11 sickle cell anemia 30.2 G6PD HBB TNF
12 human immunodeficiency virus type 1 30.2 CR1 IFNG IL10 TNF
13 bacterial sepsis 30.0 IL10 NOS2 SELE TNF
14 dengue hemorrhagic fever 30.0 FCGR2A IFNG IL10 TNF
15 hemophagocytic lymphohistiocytosis 30.0 CR1 IFNG IL10 IL18 TNF
16 plasmodium vivax malaria 29.9 G6PD ICAM1 IFNG IL10 SELE TNF
17 asthma 29.9 ICAM1 IFNG IL10 IL18 SELE TNF
18 glucosephosphate dehydrogenase deficiency 29.8 G6PD HBB HP
19 myocarditis 29.8 CD55 ICAM1 MB NOS2 TNF
20 hemolytic anemia 29.8 CD55 G6PD HBB HP
21 dermatitis, atopic 29.7 ICAM1 IFNG IL10 IL18 SELE TNF
22 alpha-thalassemia 29.6 G6PD HBB HP
23 malaria 28.9 CD36 CD55 CHIT1 CR1 DHFR FCGR2A
24 anemia, nonspherocytic hemolytic, due to g6pd deficiency 11.5
25 ovalocytosis, southeast asian 11.4
26 pemphigus foliaceus 10.5
27 punctate inner choroidopathy 10.5 IL10 TNF
28 hepatitis 10.5
29 thrombocytopenia 10.5
30 lymphoma 10.5
31 tropical endomyocardial fibrosis 10.4 IL10 TNF
32 endomyocardial fibrosis 10.4 IL10 TNF
33 cephalosporin allergy 10.4 IFNG IL10
34 rothmund-thomson syndrome 10.4
35 hyperlucent lung 10.4 IFNG IL10
36 multifocal choroiditis 10.4 IL10 TNF
37 staphylococcal toxic shock syndrome 10.4 IFNG TNF
38 tungiasis 10.4 IL10 TNF
39 autoimmune myocarditis 10.4 IFNG TNF
40 rheumatic fever 10.4 HP IL10 TNF
41 hemorrhagic fever 10.4 IFNG IL10 TNF
42 castleman disease 10.3 CR1 IFNG IL10
43 chronic graft versus host disease 10.3 IFNG IL10 TNF
44 clonorchiasis 10.3 IFNG IL10 TNF
45 burkitt lymphoma 10.3
46 aceruloplasminemia 10.3
47 acute respiratory distress syndrome 10.3
48 necrotizing ulcerative gingivitis 10.3 IL10 IL18
49 intermediate uveitis 10.3 IFNG IL10 TNF
50 orofacial granulomatosis 10.3 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:



Diseases related to Plasmodium Falciparum Malaria
Sources

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

About this section

GenomeRNAi Phenotypes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 DHFR ICAM1 IL10 IL18 NOS2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 DHFR ICAM1 IL10 IL18 NOS2 TNF

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 CD36 CD55 DHFR FCGR2A G6PD HP
2 cellular MP:0005384 10.32 CD36 DHFR G6PD HP ICAM1 IFNG
3 cardiovascular system MP:0005385 10.3 CD36 DHFR G6PD HP ICAM1 IFNG
4 homeostasis/metabolism MP:0005376 10.25 CD36 DHFR G6PD HP ICAM1 IFNG
5 growth/size/body region MP:0005378 10.22 CD36 DHFR G6PD ICAM1 IFNG IL10
6 immune system MP:0005387 10.22 CD36 CHIT1 DHFR FCGR2A HP ICAM1
7 mortality/aging MP:0010768 10.07 CD36 DHFR FCGR2A G6PD HP ICAM1
8 digestive/alimentary MP:0005381 10.04 CD36 ICAM1 IFNG IL10 IL18 NOS2
9 integument MP:0010771 9.97 DHFR ICAM1 IFNG IL10 IL18 NOS2
10 liver/biliary system MP:0005370 9.92 CD36 DHFR HP IFNG IL10 NOS2
11 muscle MP:0005369 9.81 CD36 DHFR ICAM1 IFNG IL10 IL18
12 neoplasm MP:0002006 9.5 HP ICAM1 IFNG IL10 MIF NOS2
13 vision/eye MP:0005391 9.23 CD36 ICAM1 IFNG IL10 IL18 NOS2
Sources

Drugs & Therapeutics for Plasmodium Falciparum Malaria

About this section

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amodiaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 86-42-0 2165
2
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71963-77-4 119380 68911
3
Mefloquine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53230-10-7 4046
4
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82186-77-4 6437380
5
Artesunate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 88495-63-0 5464098 6917864
6
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-34-6 4908
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
8
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 2447-57-6 17134
9
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 58-14-0 4993
10
Nevirapine Approved Phase 4,Early Phase 1 129618-40-2 4463
11
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54-05-7 2719
12
Proguanil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 500-92-5 4923
13
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80-08-0 2955
14
Atovaquone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 95233-18-4 74989
15
Quinine Approved Phase 4,Phase 3,Phase 2,Not Applicable 130-95-0 8549 3034034
16
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
18
Dihydroartemisinin Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71939-50-9 6918483
19
Lactitol Investigational Phase 4,Phase 3,Phase 1,Not Applicable 585-86-4, 585-88-6 493591
20
Piperaquine Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4085-31-8 5079497
21
Chlorproguanil Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 537-21-3 9571037 151170
22
Pyronaridine Investigational Phase 4,Phase 3,Phase 2 74847-35-1 5485198
23 Artemisinine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
25 Anthelmintics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Artemether, Lumefantrine Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antimalarials Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Artemisinins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Amodiaquine, artesunate drug combination Phase 4,Not Applicable
33 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Fanasil, pyrimethamine drug combination Phase 4,Phase 3,Phase 2,Not Applicable
39 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Not Applicable
40 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Anti-Retroviral Agents Phase 4,Early Phase 1
42 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Chloroquine diphosphate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-63-5
47 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Atovaquone, proguanil drug combination Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 378)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
2 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
3 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
4 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
5 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
6 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
7 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
8 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
9 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
10 Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
11 Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 Completed NCT03768908 Phase 4 Artemether-lumefantrine;Artesunate + Amodiaquine
12 Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
13 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
14 Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania Completed NCT03431714 Phase 4 Artesunate amodiaquine
15 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. Completed NCT02089841 Phase 4 Artemether-lumefantrine
16 Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
17 Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
18 Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
19 Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar Completed NCT03764527 Phase 4 Artemether-lumefantrine;Coadministered Artesunate plus Amodiaquine
20 Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania Completed NCT00885287 Phase 4 Artemether-lumefantrine (AL)
21 Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Completed NCT00699920 Phase 4 Coarsucam;Coartem
22 Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria Completed NCT00978172 Phase 4 artesunate and mefloquine
23 Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan Completed NCT01019408 Phase 4 Chloroquine
24 Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger Completed NCT01755559 Phase 4 Artesunate-amodiaquine;Dihydroartemisinin-piperaquine;Artemether-lumefantrine
25 Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
26 Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria Completed NCT00425763 Phase 4 AQAS
27 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
28 CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
29 Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo Completed NCT02940756 Phase 4 artesunate-amodiaquine;artemether-lumefantrine;Dihydroartemisinine-piperaquine
30 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Completed NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
31 Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic Completed NCT03783299 Phase 4 Artemether-lumefantrine;Primaquine Phosphate
32 Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area Completed NCT00935688 Phase 4
33 Tracking Resistance to Artemisinin (TRAC) Completed NCT01350856 Phase 4 Artesunate 2;Artesunate 4
34 Kintampo Trial of Combination Therapy for Malaria Completed NCT00119145 Phase 4 artesunate-amodiaquine;coartem;artesunate-lapdap
35 Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function Completed NCT00444106 Phase 4 Artesunate-mefloquine;Atovaquone-proguanil;Artemether-lumefantrine
36 Harmonized AS/MQ Efficacy Study - Thailand Completed NCT02052323 Phase 4 Artesunate/mefloquine (AS/MQ)
37 Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers Completed NCT00233337 Phase 4 Co-artemether
38 Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine Completed NCT00167739 Phase 4 Quinine plus sulfadoxine-pyrimethamine
39 Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance Completed NCT00445796 Phase 4 Artesunate;Amodiaquine
40 Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire Completed NCT01023399 Phase 4 Artesunate + Amodiaquine
41 In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy Completed NCT01976780 Phase 4 Artesunate;Artemether Lumefantrine;Mefloquine
42 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4 Flavoquine®, Camoquin® Suspension;Flavoquine®, Camoquin® Suspension
43 Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar Completed NCT00549003 Phase 4
44 Amodiaquine+Artesunate for Uncomplicated Malaria Treatment Completed NCT01213433 Phase 4 Artesunate-Amodiaquine
45 Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria Completed NCT02092766 Phase 4 artesunate;quinine
46 Plasmodium Falciparum Artemisinin Resistance Vietnam Completed NCT01775592 Phase 4 Arterakin (DHA-PPQ)
47 Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso Completed NCT01697787 Phase 4 Amodiaquine-Artesunate;Artemether-lumefantrine
48 Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
49 In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children Completed NCT02168569 Phase 4 Coartemâ„¢ (Artemether-lumefantrine combination);Coarsucamâ„¢ (Amodiaquine-artesunate combination)
50 Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Completed NCT01998295 Phase 4 Artemether/lumefantrine

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: malaria, falciparum

Sources

Genetic Tests for Plasmodium Falciparum Malaria

About this section
Sources

Anatomical Context for Plasmodium Falciparum Malaria

About this section

MalaCards organs/tissues related to Plasmodium Falciparum Malaria:

42
Testes, T Cells, Liver, Endothelial, Monocytes, Skin, Kidney
Sources

Publications for Plasmodium Falciparum Malaria

About this section

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 1800)
# Title Authors Year
1
A comparison of thick-film microscopy, rapid diagnostic test, and polymerase chain reaction for accurate diagnosis of Plasmodium falciparum malaria. ( 30866947 )
2019
2
Propensity score analysis of artesunate versus quinine for severe imported Plasmodium falciparum malaria in France. ( 30874798 )
2019
3
Glycocalyx Breakdown is Associated with Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria. ( 30753363 )
2019
4
Structured mathematical models to investigate the interactions between Plasmodium falciparum malaria parasites and host immune response. ( 30768947 )
2019
5
A population-based study of the prevalence and risk-factors of low-grade Plasmodium falciparum malaria infection in children aged 0-15 years old in northern Tanzania. ( 30843638 )
2019
6
Kinetic and cross-sectional studies on the genesis of hypoargininemia in severe pediatric falciparum malaria. ( 30718287 )
2019
7
Efficacy and Safety of Pyronaridine-Artesunate plus Single-Dose Primaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Eastern Cambodia. ( 30602520 )
2019
8
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. ( 30620055 )
2019
9
A Cross-Sectional Population Study of Geographic, Age-Specific, and Household Risk Factors for Asymptomatic Plasmodium falciparum Malaria Infection in Western Kenya. ( 30457091 )
2019
10
Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. ( 29425320 )
2018
11
Severe Plasmodium falciparum Malaria Treated With Investigational Artesunate in the United States. ( 29898630 )
2018
12
Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. ( 29534720 )
2018
13
Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate. ( 29394389 )
2018
14
DSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria. ( 29909070 )
2018
15
Etiology of Placental Plasmodium falciparum Malaria in African Women. ( 29579263 )
2018
16
Spatio-temporal distribution of PfMDR1 polymorphism among uncomplicated Plasmodium falciparum malaria cases along international border of north east India. ( 29842979 )
2018
17
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. ( 29370844 )
2018
18
Can the Therapeutically-rational Exchange (T-REX) of Glucose-6-phosphate Dehydrogenase Deficient Red Blood Cells Reduce Plasmodium falciparum Malaria Morbidity and Mortality? ( 29717302 )
2018
19
Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across CA'te da89Ivore ( 29717574 )
2018
20
Dihydroartemisinin-piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia. ( 29980936 )
2018
21
Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. ( 29764419 )
2018
22
Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. ( 29615039 )
2018
23
Posttreatment HRP2 Clearance in Patients with Uncomplicated Plasmodium falciparum Malaria. ( 29220497 )
2018
24
Sub-acute intestinal obstruction - a rare complication of Plasmodium falciparum malaria in an adult: a case report. ( 29966528 )
2018
25
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. ( 29703425 )
2018
26
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. ( 29347975 )
2018
27
Plasmodium falciparum malaria skews globin gene expression balance in in-vitro haematopoietic stem cell culture system: Its implications in malaria associated anemia. ( 29309785 )
2018
28
Kinetics of antibody responses to PfRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria. ( 29883485 )
2018
29
Epidemiological, Clinical, and Laboratory Evaluation of Plasmodium falciparum Malaria Cases Followed in Firat University Hospital: A 6-Year Retrospective Analysis. ( 29780012 )
2018
30
Multidrug-resistant Plasmodium falciparum malaria in the Greater Mekong subregion. ( 29398389 )
2018
31
Mild encephalitis/encephalopathy with a reversible splenial lesion due to Plasmodium falciparum malaria: a case report. ( 30410417 )
2018
32
Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial. ( 30668322 )
2018
33
The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria. ( 30619241 )
2018
34
Can Therapeutically-Rational Exchange (T-REX) of Thalassemic Red Blood Cells Improve the Clinical Course of Plasmodium falciparum Malaria? ( 30515048 )
2018
35
Evaluation of PTA-derived ruthenium(II) and iridium(III) quinoline complexes against chloroquine-sensitive and resistant strains of the Plasmodium falciparum malaria parasite. ( 30529881 )
2018
36
Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa? ( 30547849 )
2018
37
Letter to the editor: Is malaria re-emerging in southern Europe? Cryptic Plasmodium falciparum malaria in Malta, October 2018. ( 30563595 )
2018
38
Assessment of International Consensus Group for Haematology smear review rules among patients with Plasmodium falciparum malaria in Johannesburg, South Africa. ( 30568893 )
2018
39
Evidence of Artemisinin-Resistant Plasmodium falciparum Malaria in Eastern India. ( 30428283 )
2018
40
Cryptic severe Plasmodium falciparum malaria in a Moroccan man living in Tuscany, Italy, August 2018. ( 30326993 )
2018
41
Inducing controlled cell cycle arrest and re-entry during asexual proliferation of Plasmodium falciparum malaria parasites. ( 30409996 )
2018
42
An investigation of the Plasmodium falciparum malaria epidemic in Kavango and Zambezi regions of Namibia in 2016. ( 30252108 )
2018
43
Projecting potential spatial and temporal changes in the distribution of Plasmodium vivax and Plasmodium falciparum malaria in China with climate change. ( 30283159 )
2018
44
A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. ( 30290808 )
2018
45
Can malaria rapid diagnostic tests by drug sellers under field conditions classify children 5 years old or less with or without Plasmodium falciparum malaria? Comparison with nested PCR analysis. ( 30326926 )
2018
46
Population pharmacokinetics of mefloquine given as a 3-day artesunate-mefloquine in patients with acute uncomplicated Plasmodium falciparum malaria in a multidrug-resistant area along the Thai-Myanmar border. ( 30176888 )
2018
47
Correction: Kinetics of antibody responses to PfRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria. ( 30222763 )
2018
48
Failure of intravenous artesunate treatment for Plasmodium falciparum malaria in a splenectomized traveller: A diagnostic challenge. ( 30227244 )
2018
49
Complement Factor H Levels Associate With Plasmodium falciparum Malaria Susceptibility and Severity. ( 30087905 )
2018
50
Correction to: Individual and household characteristics of persons with Plasmodium falciparum malaria in sites with varying endemicities in Kinshasa Province, Democratic Republic of the Congo. ( 30089480 )
2018
Sources

Variations for Plasmodium Falciparum Malaria

About this section
Sources

Expression for Plasmodium Falciparum Malaria

About this section
Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.
Sources

Pathways for Plasmodium Falciparum Malaria

About this section

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.9 CD36 CD55 CHIT1 CR1 FCGR2A HBB
2
Cytokine Signaling in Immune system 67
Show member pathways
 13.31 CD36 ICAM1 IFNG IL10 IL18 NOS2
3
Allograft rejection 1 38
Show member pathways
 12.84 CD55 ICAM1 IFNG IL10 IL18 TNF
4
Immune response IL-23 signaling pathway 23
Show member pathways
 12.56 IFNG IL10 IL18 NOS2 TNF
5
Selenium Micronutrient Network 1
Show member pathways
 12.28 DHFR HBB ICAM1 IFNG TNF
6
Toll Comparative Pathway 65
Show member pathways
 12.27 IFNG MIF NOS2 TNF
7
Toxoplasmosis 38
Show member pathways
 12.18 CR1 FCGR2A IFNG IL10 NOS2 TNF
8
Tuberculosis 38
12.12 CR1 FCGR2A IFNG IL10 IL18 NOS2
9
Fluid shear stress and atherosclerosis 38
12.07 ICAM1 IFNG SELE TNF
10
Th1 Differentiation Pathway 66
Show member pathways
 12.03 IFNG IL10 IL18 TNF
11
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 12.01 CD36 FCGR2A IFNG TNF
12
Spinal Cord Injury 1
11.96 FCGR2A ICAM1 IFNG MIF NOS2 TNF
13
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.94 CD36 FCGR2A IFNG IL10 TNF
14
IL12-mediated signaling events 1
Show member pathways
 11.92 IFNG IL18 NOS2
15
TNF signaling pathway 38
11.9 ICAM1 SELE TNF
16
Interleukin-4 and 13 signaling 67
11.9 CD36 ICAM1 IL10 IL18 NOS2 TNF
17
Binding and Uptake of Ligands by Scavenger Receptors 67
Show member pathways
 11.87 CD36 HBB HP
18
Hematopoietic cell lineage 38
11.86 CD36 CD55 CR1 TNF
19
AGE-RAGE signaling pathway in diabetic complications 38
11.85 ICAM1 SELE TNF
20
Amoebiasis 38
11.85 IFNG IL10 NOS2 TNF
21
Rheumatoid arthritis 38
11.82 ICAM1 IFNG IL18 TNF
22
Salmonella infection (KEGG) 38
11.79 IFNG IL18 NOS2
23
Glucocorticoid receptor regulatory network 1
11.76 ICAM1 IFNG SELE
24
Innate Lymphoid Cell Differentiation Pathways 66
11.74 IFNG IL10 IL18 TNF
25
Pertussis 38
11.72 IL10 NOS2 TNF
26
Dendritic Cells Developmental Lineage Pathway 66
11.71 IFNG IL10 TNF
27
Staphylococcus aureus infection 38
11.66 FCGR2A ICAM1 IL10
28
ATF-2 transcription factor network 1
11.56 IFNG NOS2 SELE
29
Legionellosis 38
11.56 CR1 IL18 TNF
30
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.55 CD36 FCGR2A IFNG IL10 IL18 NOS2
31
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.53 ICAM1 IFNG MIF NOS2 SELE TNF
32
Interleukin-10 signaling 67
11.5 ICAM1 IL10 IL18 TNF
33
amb2 Integrin signaling 1
11.49 HP ICAM1 TNF
34
MSP-RON Signaling 65
11.48 IFNG IL18 NOS2 TNF
35
Type II interferon signaling (IFNG) 1
11.36 ICAM1 IFNG NOS2
36
Development and heterogeneity of the ILC family 1
11.28 IFNG IL18 TNF
37
Cytokines and Inflammatory Response 1
11.23 IFNG IL10 TNF
38
IL1 and megakaryocytes in obesity 1
11.16 ICAM1 IFNG IL18
39
African trypanosomiasis 38
11.07 HBB ICAM1 IFNG IL10 IL18 SELE
40
Malaria 38
10.97 CD36 CR1 HBB ICAM1 IFNG IL10
41
LDL Oxidation in Atherogenesis 65
10.9 CD36 ICAM1 TNF
42
Effects of Nitric Oxide 1
10.56 MB NOS2
Sources

GO Terms for Plasmodium Falciparum Malaria

About this section

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 CD55 CHIT1 HBB HP IFNG IL10
2 cell surface GO:0009986 9.63 CD36 CD55 CR1 ICAM1 MIF TNF
3 secretory granule membrane GO:0030667 9.58 CD55 CR1 FCGR2A
4 endocytic vesicle lumen GO:0071682 9.46 HBB HP
5 tertiary granule lumen GO:1904724 9.43 CHIT1 HBB HP
6 haptoglobin-hemoglobin complex GO:0031838 9.37 HBB HP
7 extracellular space GO:0005615 9.36 CD36 CHIT1 HBB HP ICAM1 IFNG
8 membrane raft GO:0045121 9.35 CD36 CD55 ICAM1 SELE TNF
9 extracellular exosome GO:0070062 10.03 CD55 CR1 G6PD HBB HP ICAM1

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.97 IL10 IL18 MIF SELE TNF
2 defense response to bacterium GO:0042742 9.95 HP IL10 NOS2 TNF
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 CD36 ICAM1 MIF TNF
4 leukocyte migration GO:0050900 9.92 ICAM1 MIF SELE TNF
5 response to lipopolysaccharide GO:0032496 9.88 ICAM1 IL10 NOS2 SELE
6 immune response GO:0006955 9.88 CD36 CHIT1 IFNG IL10 IL18 TNF
7 response to bacterium GO:0009617 9.85 CD36 CHIT1 NOS2
8 response to organic substance GO:0010033 9.84 HP IL10 TNF
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 CD36 ICAM1 MIF
10 viral entry into host cell GO:0046718 9.83 CD55 CR1 ICAM1
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 CD36 ICAM1 IL18 TNF
12 regulation of insulin secretion GO:0050796 9.81 IFNG NOS2 TNF
13 response to hydrogen peroxide GO:0042542 9.77 HBB HP MB
14 negative regulation of gene expression GO:0010629 9.77 CD36 IFNG MIF NOS2 TNF
15 positive regulation of cell death GO:0010942 9.76 CD36 HBB HP
16 interleukin-12-mediated signaling pathway GO:0035722 9.73 IFNG IL10 MIF
17 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.68 CD36 IL18
18 oxygen transport GO:0015671 9.68 HBB MB
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
20 regulation of regulatory T cell differentiation GO:0045589 9.67 CR1 IFNG
21 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 TNF
22 positive regulation of cytokine secretion GO:0050715 9.65 IL10 MIF TNF
23 cellular response to lipopolysaccharide GO:0071222 9.65 CD36 ICAM1 IL10 NOS2 TNF
24 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
25 regulation of removal of superoxide radicals GO:2000121 9.63 CD36 DHFR
26 cytokine-mediated signaling pathway GO:0019221 9.63 CD36 ICAM1 IL10 IL18 NOS2 TNF
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
28 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.61 ICAM1 TNF
29 positive regulation of neuroinflammatory response GO:0150078 9.61 IL18 TNF
30 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.59 MIF TNF
31 neutrophil degranulation GO:0043312 9.56 CD36 CD55 CHIT1 CR1 FCGR2A HBB
32 positive regulation of killing of cells of other organism GO:0051712 9.55 IFNG NOS2
33 type 2 immune response GO:0042092 9.54 IL10 IL18
34 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
35 negative regulation of growth of symbiont in host GO:0044130 9.5 CD36 IL10 TNF
36 receptor biosynthetic process GO:0032800 9.49 IL10 TNF
37 positive regulation of blood microparticle formation GO:2000334 9.46 CD36 TNF
38 positive regulation of vitamin D biosynthetic process GO:0060557 9.43 IFNG TNF
39 positive regulation of nitric oxide biosynthetic process GO:0045429 9.02 CD36 HBB ICAM1 IFNG TNF
40 regulation of signaling receptor activity GO:0010469 10.03 IFNG IL10 IL18 MIF TNF

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.43 CD55 CR1 ICAM1
2 oxygen carrier activity GO:0005344 9.32 HBB MB
3 hemoglobin binding GO:0030492 9.16 HBB HP
4 NADP binding GO:0050661 9.13 DHFR G6PD NOS2
5 cytokine activity GO:0005125 9.02 IFNG IL10 IL18 MIF TNF
Sources

Sources for Plasmodium Falciparum Malaria

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....